Incidence and risk factors of acute kidney injury in COVID-19 patients with and without acute respiratory distress syndrome (ARDS) during the first wave of COVID-19: a systematic review and Meta-Analysis

• Published in: Renal failure Vol. 43; no. 1; pp. 1621 - 1633
• Main Authors: Alenezi, Faraj K., Almeshari, Mohammed A., Mahida, Rahul, Bangash, Mansoor N., Thickett, David R., Patel, Jaimin M.
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 01.01.2021; Taylor & Francis Ltd; Taylor & Francis Group
• Subjects: Acute kidney injury; Acute Kidney Injury - epidemiology; acute respiratory distress syndrome; Clinical Study; Comorbidity; Coronaviruses; COVID-19; COVID-19 - complications; COVID-19 - epidemiology; Humans; Incidence; Kidney diseases; kidney replacement therapy; Kidneys; Meta-analysis; Mortality; Patients; Renal function; Respiratory distress syndrome; Respiratory Distress Syndrome - complications; Respiratory Distress Syndrome - epidemiology; Risk Factors; Systematic review; COVID-19; Acute kidney injury; kidney replacement therapy; acute respiratory distress syndrome; meta-analysis; mortality; systematic review
• ISSN: 0886-022X; 1525-6049
• DOI: 10.1080/0886022X.2021.2011747

Acute kidney injury (AKI) is common among patients with COVID-19. However, AKI incidence may increase when COVID-19 patients develop acute respiratory distress syndrome (ARDS). Thus, this systematic review and meta-analysis aimed to assess the incidence and risk factors of AKI, need for kidney replacement therapy (KRT), and mortality rate among COVID-19 patients with and without ARDS from the first wave of COVID-19. The databases MEDLINE and EMBASE were searched using relevant keywords. Only articles available in English published between December 1, 2019, and November 1, 2020, were included. Studies that included AKI in COVID-19 patients with or without ARDS were included. Meta-analyses were conducted using random-effects models. Out of 618 studies identified and screened, 31 studies met the inclusion criteria. A total of 27,500 patients with confirmed COVID-19 were included. The overall incidence of AKI in patients with COVID-19 was 26% (95% CI 19% to 33%). The incidence of AKI was significantly higher among COVID-19 patients with ARDS than COVID-19 patients without ARDS (59% vs. 6%, p < 0.001). Comparing ARDS with non-ARDS COVID-19 cohorts, the need for KRT was also higher in ARDS cohorts (20% vs. 1%). The mortality among COVID-19 patients with AKI was significantly higher (Risk ratio = 4.46; 95% CI 3.31-6; p < 0.00001) than patients without AKI. This study shows that ARDS development in COVID-19-patients leads to a higher incidence of AKI and increased mortality rate. Therefore, healthcare providers should be aware of kidney dysfunction, especially among elderly patients with multiple comorbidities. Early kidney function assessment and treatments are vital in COVID-19 patients with ARDS.